Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calcium-dependent antigen binding as a novel modality for antibody recycling by endosomal antigen dissociation.

mAbs·2015
Same author

pH-dependent antigen-binding antibodies as a novel therapeutic modality.

Biochimica et biophysica acta·2014
Same author

Positron annihilation in cardo-based polymer membranes.

The journal of physical chemistry. B·2014
Same author

Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.

Molecular immunology·2013

Related Experiment Video

Updated: May 10, 2026

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
04:47

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

Published on: February 23, 2018

Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131).

F Mimoto1, H Katada, S Kadono

  • 1Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.

Protein Engineering, Design & Selection : PEDS
|June 8, 2013
PubMed
Summary

Researchers developed a novel antibody Fc variant that selectively binds to FcγRIIb, enhancing therapeutic efficacy without unwanted FcγRIIa interactions. This breakthrough improves antibody-based treatments by boosting desired immune responses.

Keywords:
Fc engineeringFcγRIIbantibody engineeringinhibitory FcγRplatelet activation

More Related Videos

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

Related Experiment Videos

Last Updated: May 10, 2026

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
04:47

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

Published on: February 23, 2018

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

Area of Science:

  • Immunology
  • Biochemistry
  • Structural Biology

Background:

  • Engaging inhibitory Fc gamma receptor IIb (FcγRIIb) is a promising strategy to enhance antibody therapeutics.
  • Existing Fc variants with improved FcγRIIb binding also bind FcγRIIa, limiting therapeutic potential due to structural similarities.

Purpose of the Study:

  • To engineer a novel Fc variant with selective high-affinity binding to FcγRIIb.
  • To differentiate binding affinity between FcγRIIb and FcγRIIa allotypes (R131 and H131).

Main Methods:

  • Structure-guided design and comprehensive mutagenesis of the Fc region.
  • Analysis of Fc/FcγRIIb complex crystal structure.
  • Biochemical assays to measure binding affinities and in vitro functional assays.

Main Results:

  • A novel Fc variant demonstrated >200-fold increased binding affinity to FcγRIIb compared to wild-type IgG1.
  • This variant showed comparable or lower binding affinity to FcγRIIa(R131) and FcγRIIa(H131) allotypes.
  • The variant did not induce platelet aggregation in vitro, unlike Fc variants binding both FcγRIIb and FcγRIIa.
  • Application to an agonistic anti-CD137 IgG1 antibody significantly enhanced its activity.

Conclusions:

  • A novel Fc variant with selective FcγRIIb enhancement was successfully engineered.
  • This variant offers a precise tool for improving antibody therapeutic efficacy by modulating immune responses.
  • The selective FcγRIIb engagement avoids FcγRIIa-mediated side effects, paving the way for safer and more effective antibody therapies.